Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142059 | 0.82 | KMT2A (0.46) | ALDH1A1KDM4EHSD17B10GABRA1GABRG2 | |
| SCHEMBL388866 | 0.82 | ABL1 (0.42) | ALDH1A1KDM4EHSD17B10ABL1GABRA1 | |
| SCHEMBL28458688 | 0.81 | ESR1 (0.38) | ALDH1A1HSD17B10MAPK10KMT2AGAA | |
| SCHEMBL392990 | 0.81 | ABL1 (0.41) | ALDH1A1KDM4EABL1GABRA1GABRG2 | |
| SCHEMBL25309806 | 0.79 | HSD17B10 (0.48) | ALDH1A1KDM4EHSD17B10GABRA1GABRG2 | |
| SCHEMBL392388 | 0.79 | ABL1 (0.41) | ALDH1A1KDM4EABL1GABRA1GABRG2 | |
| SCHEMBL12503146 | 0.79 | SMN1; SMN2 (0.42) | ALDH1A1KDM4EHSD17B10GABRA1GABRG2 | |
| SCHEMBL15050905 | 0.78 | ABL1 (0.47) | ALDH1A1KDM4EHSD17B10ABL1GABRA1 | |
| SCHEMBL14269810 | 0.76 | ABL1 (0.46) | ALDH1A1KDM4EHSD17B10ABL1GABRA1 | |
| SCHEMBL22470690 | 0.75 | GABRG2 (0.48) | ALDH1A1KDM4EHSD17B10GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111704611-B | Aryl spiro SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-111704611-A | Aryl spiro SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-2411366-B1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2411366-B1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2364973-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | disclosed |
| CN-102942522-A | Heterocyclic inhibitors of mek and methods of use thereof | ARRAY BIOPHARMA INC | 2013-02-27 | — | — | CN | disclosed |
| CN-102898364-A | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC | 2013-01-30 | — | — | CN | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008125820-A1 | COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | ALDH1A1 3754/4885KDM4E 245/4885HSD17B10 3416/4885 |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1723/4885KDM4E 665/4885HSD17B10 3139/4885 |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | BRAF, NRAS, MAP3K1 | ALDH1A1 2121/4885KDM4E 2205/4885HSD17B10 2519/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1992/4885KDM4E 728/4885HSD17B10 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.